Seven patients with carcinomatous meningitis were administered intrathecal I-131 labelled monoclonal antibody HMFG1. Clinical responses were seen in two patients, with a long term survivor at 32 months. Aseptic meningitis occurred in 4/7 patients, but more serious toxicity was observed in the form of seizures (2/7 patients) and myelosuppression (3/7 patients). Partial obliteration of the subarachnoid space was identified as a potential problem in patients with advanced disease. Many of these problems are circumvented by the direct instillation of these reagents into body cavities where tumour cells are directly exposed to high concentration of immunoconjugate. These techniques were pioneered in the coelomic cavities,'"'7 and subsequently evaluated in the subarachnoid space of patients with neoplastic meningitis.'8 Experience to date with intracavitary monoclonal antibody radioimmunotherapy has largely been with iodine-131 and yttrium-90.
The development of monoclonal antibodies defining tumour associated antigens has significantly enhanced the field of diagnostic histopathology. ' 2 As a natural extension of their success as immunocytochemical reagents, extensive investigation has explored their potential as vectors for targeting radionuclides, 3 toxins" or drugs7 to tumours. In animal xenograft tumour models, specific targeting of radioimmunoconjugates to tumour sites has been demonstrated. 89 Therapeutic effect has also been observed in these models as evidenced by shrinkage and even cure of tumours.'1 '2 In contrast to animal studies, the intravenous administration of monoclonal antibody immunoconjugates into patients with tumours has been consistently disappointing. In most studies, the percentage of the total injected dose of immunoconjugate localising within tumour tissue has been extremely low (approximately 10-3% of the injected dose per gram of tumour) and this has been attributed to several factors. Firstly, the volume of distribution of these radiopharmaceuticals in humans is several orders of magnitude greater than in laboratory animals and this dilutional effect clearly reduces the concentration of immunoconjugate at tumour sites. '3 Secondly, the penetration of immunoconjugate into tumours may be restricted by limited permeability of these macromolecules across lipid membrane blood/tumour barriers.'3 Other contributing factors cited have included the presence of tumour-shed antigens,'4 and the sequestration of blood pool immunoconjugate within abdominal viscera. '3 Many of these problems are circumvented by the direct instillation of these reagents into body cavities where tumour cells are directly exposed to high concentration of immunoconjugate. These techniques were pioneered in the coelomic cavities,'"'7 and subsequently evaluated in the subarachnoid space of patients with neoplastic meningitis. '8 Experience to date with intracavitary monoclonal antibody radioimmunotherapy has largely been with iodine-131 and yttrium-90.
These predominantly beta-emitting radionuclides deliver short range energy to micrometastases, whilst sparing normal body tissues. Neoplastic meningitis is characterised by the existence of thin sheets of leptomeningeal tumour and free floating malignant cell clusters within the subarachnoid space. It is therefore theoretically amenable to specifically targeted short range radiation delivered via the CSF pathways. In preliminary studies of antibody guided radiation in neoplastic meningitis, demonstrable therapeutic responses were seen in patients with relatively radiosensitive neuro-ectodermal and lymphoid tumours.'519 The efficacy of this method for the treatment of neoplastic meningitis secondary to carcinoma (carcinomatous meningitis) is also currently being evaluated and we report here the results obtained with seven patients treated by intrathecal administration of I-131 labelled monoclonal antibody HMFG1.
Methods

Antibody
The antibody HMFG1 was developed against the human milk fat globule20 and binds to an epitope on the high molecular weight glycoprotein (polymorphic epithelial mucin, PEM). Patients were scanned as soon and as often as their clinical condition permitted. In cases 2 and 3, clinical circumstances prevented acquisition of scanning biodistribution data.
Evaluation of clinical response Patients were evaluated for response if they had received neither chemotherapy nor radiotherapy to all evaluable sites within the preceding six weeks. These conditions were waived if the patients had clear evidence of disease progression in the intervening period. (fig 2) . In case 3, a positive diagnostic assay result became negative after therapy. In this same group of-patients with the exception of case 3, serum HMFG1 (PEM) mucin increased following therapy, indicating progressive systemic disease (fig 3) . Serum levels of HMFG1 (PEM) mucin in case 3 remained approximately constant, indicating stable systemic disease. Indeed, survivals of two to three years have been reported in occasional patients with neoplastic meningitis complicating breast carcinoma.29138-0 Although clinical responses have followed conventional therapeutic methods, the nonspecific nature of these modalities results in severe dose-limiting toxicity and consequent limitations in efficacy. As a possible solution to this therapeutic dilemma, several investigators have advocated the intrathecal instillation of colloidal radioactive gold4' or yttrium-DTPA. 42 The short range beta-particle emissions from these radionuclides deposit their radiation energy within leptomeningeal tissues Emphasis should therefore be placed on the diagnosis of minimal disease and on establishment of complete patency of the craniospinal subarachnoid space before therapy. The addition of Indium-il1-DTPA ventriculography may complement CT myelography in this assessment,49 and areas of reduced radionuclide distribution may be externally irradiated before intrathecal radioimmunotherapy.
In conclusion, we suggest that intrathecal instillation of monoclonal antibody radioimmunoconjugates may produce a worthwhile clinical response in carcinomatous meningitis, although this may be less marked than that observed in more radiosensitive lymphoid and primary neuroectodermal tumours. Modifications in the methodology may further enhance the therapeutic efficacy of the technique. Firstly, monoclonal antibodies defining alternative epithelium specific antigens might be employed with advantage. A theoretical concern with monoclonal antibody HMFG1 relates to the glycoprotein antigen (PEM) it defines. Polymorphic epithelial mucin (PEM) is liberated from the cell surface into CSF and this may reduce tumour cell targeting of immunoconjugates.14 Further variations may include multiple doses, alternative radionuclides or the use of antibody cocktail mixtures to account for heterogeneity of tumour cell antigen expression. 50 We believe that intrathecal radioimmunotherapy should be pursued as an alternative method of palliative treatment for carcinomatous meningitis, as presently existing methods of treatment are clinically inadequate. The value of this technique will become more apparent when a larger experience has been accumulated.
